Pay in 4 interest-free payments of $5.57 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Novel Dual GLP-1/GIP Receptor Agonists Show Neuroprotective Effects in Alzheimers and Parkinsons Disease Models
These mechanistic differences inform clinical decision-making and help healthcare providers select the most appropriate therapy for individual patients based on their specific needs and tolerability profiles
No patients needed a further increase to 14 mg/day during the follow-up
This cost differential has enormous implications for treatment duration
Additional Phase 3 readouts in diabetes, cardiovascular disease, and several other indications are scheduled through 2026
US$ 27.92
US$ 28.51
US$ 24.87
US$ 28.33
.jpg)
US$ 23.66
US$ 28.78
US$ 28.53
US$ 28.53
:max_bytes(150000):strip_icc()/GettyImages-2203380329-06d7f8c655d54856aa6af455acae8035.jpg)
